Global Carcinoembryonic Antigen (CEA) Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Carcinoembryonic Antigen (CEA) Market Research Report 2024
Carcinoembryonic antigen (CEA) describes a set of highly related glycoproteins involved in cell adhesion.
According to MRAResearch’s new survey, global Carcinoembryonic Antigen (CEA) market is projected to reach US$ 2328 million in 2033, increasing from US$ 1753.7 million in 2022, with the CAGR of 4.1% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Carcinoembryonic Antigen (CEA) market research.
Increasing consumption of alcohol and sedentary lifestyle are likely to boost the growth of colorectal cancer over the forecast period.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Carcinoembryonic Antigen (CEA) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Roche Diagnostics
Abbott Diagnostics
Quest Diagnostics
Segment by Type
CD66a
CD66b
CD66c
CD66d
CD66e
CD66f
Colorectal Cancer
Pancreatic Cancer
Ovarian Cancer
Breast Cancer
Thyroid Cancer
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Carcinoembryonic Antigen (CEA) report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to MRAResearch’s new survey, global Carcinoembryonic Antigen (CEA) market is projected to reach US$ 2328 million in 2033, increasing from US$ 1753.7 million in 2022, with the CAGR of 4.1% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Carcinoembryonic Antigen (CEA) market research.
Increasing consumption of alcohol and sedentary lifestyle are likely to boost the growth of colorectal cancer over the forecast period.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Carcinoembryonic Antigen (CEA) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Roche Diagnostics
Abbott Diagnostics
Quest Diagnostics
Segment by Type
CD66a
CD66b
CD66c
CD66d
CD66e
CD66f
Segment by Application
Colorectal Cancer
Pancreatic Cancer
Ovarian Cancer
Breast Cancer
Thyroid Cancer
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Carcinoembryonic Antigen (CEA) report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source